Clinical trials

BioContract is a manufacturer of a genetically modified melanoma vaccine AGI-101H for clinical trials

AGITAM

A Phase I/IIa Open-label Bridging Safety and Pharmacodynamic Study of a New Formulation of 6 month extended Dosing with AGI-101H vaccine in the Treatment of Patients with Advanced Melanoma

ASAS

AGI-101H vaccine in the Treatment of Patients with Advanced Melanoma Long Term Safety and Survival Follow up

ETAM

Extended Treatment For Advanced Melanoma Patients Transferring From Trials 2-5 (ETAM 2-5)